Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

New easy-to-use risk calculator helps predict heart failure patients' chances of survival

A UCLA team has developed an easy-to-use "risk calculator" that helps predict heart failure patients' chances of survival for up to five years and assists doctors in determining whether more or less aggressive treatment is appropriate.

23 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Doxorubicin is a widely used as a component of chemotherapy regimes; however, the use of doxorubicin is associated with severe cardiotoxicity. It is unclear exactly how doxorubicin promotes cardiotoxicity, but it has been proposed that doxorubicin-associated cardiomyopathy develops as the result of reactive oxygen species (ROS) production and iron accumulation.

2 Jan 2014

Texas Children's Hospital recognized as first Accredited Pediatric Heart Failure Institute in Texas

Texas Children's Hospital is proud to be named the first Accredited Pediatric Heart Failure Institute in Texas by The Healthcare Accreditation Colloquium. The Colloquium made the announcement following nearly a year of work and an in-depth onsite review on Dec. 16.

21 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Researchers identify new method to predict outcomes in heart failure patients

Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.

16 Dec 2013

New guidelines to manage heart failure in children

Heart failure in children is an important cause of childhood health problems and death. The Children's Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric Cardiology Association, has developed new guidelines to assist practitioners in primary care and emergency departments to recognize and successfully manage heart failure in children with undiagnosed heart disease and symptoms of possible heart failure.

12 Dec 2013

New guidelines developed to manage heart failure in children with undiagnosed heart disease

12 Dec 2013

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism within the heart, measured using a noninvasive magnetic resonance imaging test, is a significant predictor of clinical outcomes, independent of a patient's symptoms or the strength of the heart's ability to pump blood, known as the ejection fraction.

11 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

Leading cardiologists at The Mount Sinai Hospital have contributed to the development of a new classification system called MOGE(S) for cardiomyopathies, the diseases of the heart muscle which can lead to heart enlargement and heart failure.

4 Dec 2013

Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing, today announces that it is launching a CE/IVD labeled MID kit for Illumina MiSeq together with three new germline mutation detection MASTRTM kits enabling the identification of individuals at risk for maturity onset diabetes of the young, autosomal dominant hypercholesterolemia, and hypertrophic cardiomyopathy.

2 Dec 2013

Researchers to discuss effects of alcohol on immune system at AIRIG meeting

On Nov. 22, leading alcohol researchers from the United States and Europe will present the latest findings on how alcohol impairs the immune system.

22 Nov 2013

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia, Inc., a leader in cardiovascular regenerative medicine, today announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT).

20 Nov 2013

Researchers study safety of transendocardial stem cell injection in patients with ischemic cardiomyopathy

Alan W. Heldman, M.D., of the University of Miami Miller School of Medicine, and colleagues conducted a study to examine the safety of transendocardial stem cell injection with autologous mesenchymal stem cells and bone marrow mononuclear cells in patients with ischemic cardiomyopathy.

19 Nov 2013

Heart disease: The leading cause of deaths related to pregnancy in California

Heart disease is the leading cause of women's pregnancy-related deaths in California - but nearly one-third could be prevented, according to research presented at the American Heart Association's Scientific Sessions 2013.

18 Nov 2013

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Researchers from the Cardiovascular Institute at Rhode Island, The Miriam and Newport hospitals will present 22 abstracts, both poster and oral presentations, at the upcoming American Heart Association Scientific Sessions, to be held in Dallas November 16-20, 2013. Scientific Sessions is the foremost cardiovascular research meeting in the U.S., with more than 18,000 cardiovascular experts from more than 105 countries in attendance.

16 Nov 2013

Scientists join patients to address Friedreich's Ataxia

The Spanish Federation of Ataxia (FEDAES)—in representation of the GENEFA Platform for a Friedreich's Ataxia cure—, the Babel Family association for biomedical research into Friedreich's Ataxia, the "Centro de Biología Molecular Severo Ochoa" (CMBSO), and the Institute for Research in Biomedicine (IRB Barcelona) have signed an agreement through which these patients' associations will fund, by means of donations, a 3-year research project addressing Friedreich's Ataxia.

16 Nov 2013

New study could help lead to prevention and treatment of heart failure in diabetics

Researchers from the University of Texas Medical Branch at Galveston have discovered one of the pathogenic components of diabetes in the heart, as published in the Journal of Biological Chemistry.

7 Nov 2013

REDDSTAR plenary meeting to be held in Berlin on Nov 5 and 6

'Diabetes- can stem cells help?' is a free, public event that will be held on Monday, 4 November 2013 from 19:00- 20:30 at The Ruin located within the Berlin Museum of Medical History, Charité. Diabetes and stem cell researchers from around Europe will assemble for a REDDSTAR plenary meeting hosted by Charité in Berlin on November 5 and 6th.

30 Oct 2013